Should Thiotepa-Based Regimens Be the New Transplant Conditioning Strategy for Primary Central Nervous System Lymphoma? | JAMA Oncol;7(7): 1003-1004, 2021 07 01. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Should Thiotepa-Based Regimens Be the New Transplant Conditioning Strategy for Primary Central Nervous System Lymphoma?

Hill, John M; Meehan, Kenneth R.

Affiliation

Hill JM; Transplant and Cellular Therapy Program, Dartmouth-Hitchcock Medical Center and Norris Cotton Cancer Center, Lebanon, New Hampshire.
Meehan KR; Transplant and Cellular Therapy Program, Dartmouth-Hitchcock Medical Center and Norris Cotton Cancer Center, Lebanon, New Hampshire.

JAMA Oncol ; 7(7): 1003-1004, 2021 07 01.

Article in En | MEDLINE | ID: mdl-33956089

Subject(s)

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thiotepa / Lymphoma Limits: Humans Language: En Journal: JAMA Oncol Year: 2021 Document type: Article

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thiotepa / Lymphoma Limits: Humans Language: En Journal: JAMA Oncol Year: 2021 Document type: Article